Oncolytics Biotec receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oncolytics Biotech Inc (ONCY)
Oncolytics Biotech Inc stock price live, this page displays NASDAQ ONCY stock exchange data. View the ONCY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Oncolytics Biotech Inc real time stock price chart below.
What Is the Oncolytics Biotech Inc Stock Price Today?
The Oncolytics Biotech Inc stock price today is 1.030.
What Is the Stock Symbol for Oncolytics Biotech Inc?
The stock symbol for Oncolytics Biotech Inc is ""ONCY.""
What Stock Exchange Does Oncolytics Biotech Inc Trade On?
Oncolytics Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is Oncolytics Biotech Inc a Good Stock to Buy?
Determining whether Oncolytics Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ONCY quote. (ISIN: CA6823108759)
What Is the Oncolytics Biotech Inc Stock Price Today?
The Oncolytics Biotech Inc stock price today is 1.030.
What Is the Stock Symbol for Oncolytics Biotech Inc?
The stock symbol for Oncolytics Biotech Inc is ""ONCY.""
What Stock Exchange Does Oncolytics Biotech Inc Trade On?
Oncolytics Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is Oncolytics Biotech Inc a Good Stock to Buy?
Determining whether Oncolytics Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ONCY quote. (ISIN: CA6823108759)
Fair Value
An estimate of a Oncolytics Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.950
1.040
52 wk Range
0.326
1.530
ONCY Scorecard
Full Analysis
3 analysts have revised their earnings upwards for the upcoming period
ONCY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Oncolytics Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.9501.040
52 wk Range
0.3261.530
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ONCY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Oncolytics Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 6K Oncolytics Biotech Inc For: 23 July
- Investing.com
- Oncolytics Biotec receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 6K Oncolytics Biotech Inc For: 29 July
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Oncolytics Biotech Inc Company Profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Oncolytics Biotech Inc SWOT Analysis
Pela's Promise | Oncolytics Biotech's lead candidate, pela, shows potential in HR+/HER2- metastatic breast cancer, with ongoing trials and regulatory support driving optimism |
Expanding Horizons | Delve into Oncolytics' strategic move into pancreatic cancer, broadening its oncology pipeline and market potential beyond breast cance |
Regulatory Tailwinds | FDA's support for progression-free survival as a primary endpoint could accelerate pela's path to market, streamlining trial design and costs |
Financial Outlook | Analysts project a $6.00 price target, reflecting confidence in pela's potential despite partnership delays and the need for continued funding |
Oncolytics Biotech Inc Earnings Call Summary for Q4/2024
- Q4 net loss increased to $8M from $3.9M YoY; EPS of -$0.1 beat -$0.1171 forecast
- Stock fell 4.75% post-earnings; company maintains $15.9M cash, 2.99x current ratio
- Advancing Pelarirep trials in breast, anal, pancreatic cancers; CEO search ongoing
- Full-year net loss $31.7M vs $27.8M in 2023; cash burn $27M, down from $28.4M
- Execs highlight Pelarirep's potential for 55,000 breast cancer patients; clinical data "exceeding expectations"
Last Updated: 07/03/2025, 15:42
Read Full TranscriptCompare ONCY to Peers and Sector
Metrics to compare | ONCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCYPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.7x | −5.2x | −0.6x | |
PEG Ratio | −2.12 | 0.06 | 0.00 | |
Price/Book | 23.5x | 0.1x | 2.6x | |
Price / LTM Sales | - | 2.0x | 3.3x | |
Upside (Analyst Target) | 326.6% | 103.4% | 39.0% | |
Fair Value Upside | Unlock | 15.7% | 4.9% | Unlock |
Earnings
Latest Release
Aug 08, 2025
EPS / Forecast
-0.07 / -0.0885
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Oncolytics Biotech Trade On?
Oncolytics Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Oncolytics Biotech?
The stock symbol for Oncolytics Biotech is "ONCY."
What Is the Oncolytics Biotech Market Cap?
As of today, Oncolytics Biotech market cap is 103.37M.
What Is Oncolytics Biotech's Earnings Per Share (TTM)?
The Oncolytics Biotech EPS (TTM) is -0.37.
When Is the Next Oncolytics Biotech Earnings Date?
Oncolytics Biotech will release its next earnings report on 11 Nov 2025.
From a Technical Analysis Perspective, Is ONCY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Oncolytics Biotech Stock Split?
Oncolytics Biotech has split 1 times.
How Many Employees Does Oncolytics Biotech Have?
Oncolytics Biotech has 28 employees.
What is the current trading status of Oncolytics Biotech (ONCY)?
As of 26 Aug 2025, Oncolytics Biotech (ONCY) is trading at a price of 1.03, with a previous close of 0.99. The stock has fluctuated within a day range of 0.95 to 1.04, while its 52-week range spans from 0.33 to 1.53.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.